Anika Therapeutics (ANIK) director awarded 10,402 RSUs in stock grant

Q: What did director John B. Henneman III receive in this Anika (ANIK) Form 4 filing?

Director John B. Henneman III received 10,402 restricted stock units (RSUs) of Anika Therapeutics common stock. These RSUs are an equity compensation award that increase his direct holdings to 65,273 shares once fully vested and settled into stock.

Q: How do the 10,402 RSUs granted to Anika (ANIK) director Henneman vest?

The 10,402 RSUs vest in full on the earlier of the 2027 annual stockholder meeting or June 18, 2027 . Once vested, each RSU converts into one share of Anika Therapeutics common stock, subject to the award’s standard terms and conditions.

Q: Did Anika (ANIK) director Henneman buy these 10,402 shares on the open market?

No, the 10,402 shares were received as a grant of restricted stock units , not an open-market purchase. The Form 4 transaction code "A" indicates a grant or award acquisition as part of compensation, with a reported price per share of $0.0000 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

HENNEMAN JOHN B III reported acquisition or exercise transactions in this Form 4 filing.

Anika Therapeutics director John B. Henneman III received an equity award of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award was granted at no cash cost and increases his direct holdings to 65,273 common shares.

Each RSU represents a contingent right to receive one share of Anika’s common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with long-term shareholder outcomes.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HENNEMAN JOHN B III

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,402	$0.00	--

Holdings After Transaction: Common Stock — 65,273 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 10,402 shares Holding after transaction: 65,273 shares Grant price per share: $0.0000 per share +1 more

4 metrics

RSUs granted 10,402 shares Restricted stock units awarded on June 18, 2026

Holding after transaction 65,273 shares Total direct Anika common shares following the grant

Grant price per share $0.0000 per share Reported transaction price for RSU award

Vesting date Earlier of 2027 annual meeting or June 18, 2027 Full vesting trigger for RSU award

Key Terms

restricted stock units ("RSUs"), contingent right, vest in full

3 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company's common stock."

vest in full financial

"The RSUs vest in full on the earlier of the 2027 annual meeting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:30 PM Accepted by SEC EDGAR 06/23/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENNEMAN JOHN B III

(Last)

(First)

(Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD

MASSACHUSETTS

01730

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		A		10,402⁽¹⁾	A	$0	65,273	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

	/s/ John B. Henneman, III	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did director John B. Henneman III receive in this Anika (ANIK) Form 4 filing?

Director John B. Henneman III received 10,402 restricted stock units (RSUs) of Anika Therapeutics common stock. These RSUs are an equity compensation award that increase his direct holdings to 65,273 shares once fully vested and settled into stock.

How do the 10,402 RSUs granted to Anika (ANIK) director Henneman vest?

The 10,402 RSUs vest in full on the earlier of the 2027 annual stockholder meeting or June 18, 2027. Once vested, each RSU converts into one share of Anika Therapeutics common stock, subject to the award’s standard terms and conditions.

Did Anika (ANIK) director Henneman buy these 10,402 shares on the open market?

No, the 10,402 shares were received as a grant of restricted stock units, not an open-market purchase. The Form 4 transaction code "A" indicates a grant or award acquisition as part of compensation, with a reported price per share of $0.0000.

What is director Henneman’s shareholding in Anika (ANIK) after this RSU grant?

After the RSU grant, director John B. Henneman III is reported to hold 65,273 shares of Anika Therapeutics common stock directly. This figure reflects his total direct ownership following the award, as disclosed in the Form 4 filing details.

What does each RSU in Anika (ANIK) director Henneman’s award represent?

Each RSU represents a contingent right to receive one share of Anika’s common stock. The units convert into actual shares only upon vesting, which in this case occurs by the earlier of the 2027 annual meeting or June 18, 2027, under the award terms.